期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 22, 期 14, 页码 -出版社
MDPI
DOI: 10.3390/ijms22147398
关键词
MBC; metaplastic breast carcinoma; EMT; epithelial-mesenchymal transition immune system
资金
- Instituto de Salud Carlos III (ISCIII) [PI19/01331]
- CIBERONC [CB16/12/00316, CB16/12/00449]
- European Development Regional Fund. 'A way to achieve Europe' (FEDER)
- Spanish Association Against Cancer Scientific Foundation
Metaplastic breast carcinoma (MBC) is a rare triple negative invasive cancer with poor prognosis. The resistance mechanisms of MBC may involve epithelial-mesenchymal transition (EMT) and immune response, distinguishing it from other types of breast cancer.
Metaplastic breast carcinoma (MBC) is a heterogeneous group of infrequent triple negative (TN) invasive carcinomas with poor prognosis. MBCs have a different clinical behavior from other types of triple negative breast cancer (TNBC), being more resistant to standard chemotherapy. MBCs are an example of tumors with activation of epithelial-mesenchymal transition (EMT). The mechanisms involved in EMT could be responsible for the increase in the infiltrative and metastatic capacity of MBCs and resistance to treatments. In addition, a relationship between EMT and the immune response has been seen in these tumors. In this sense, MBC differ from other TN tumors showing a lower number of tumor-infiltrating lymphocytes (TILS) and a higher percentage of tumor cells expressing programmed death-ligand 1 (PD-L1). A better understanding of the relationship between the immune system and EMT could provide new therapeutic approaches in MBC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据